A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
A polymerase-chain-reaction assay of 21 genes performed on paraffin-embedded samples from women with node-negative, estrogen-receptor–positive breast cancer was the basis for calculating a score for the risk of distant recurrence. The difference in risk between women with low and high recurrence sco...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2004-12, Vol.351 (27), p.2817-2826 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2826 |
|---|---|
| container_issue | 27 |
| container_start_page | 2817 |
| container_title | The New England journal of medicine |
| container_volume | 351 |
| creator | Paik, Soonmyung Shak, Steven Tang, Gong Kim, Chungyeul Baker, Joffre Cronin, Maureen Baehner, Frederick L Walker, Michael G Watson, Drew Park, Taesung Hiller, William Fisher, Edwin R Wickerham, D. Lawrence Bryant, John Wolmark, Norman |
| description | A polymerase-chain-reaction assay of 21 genes performed on paraffin-embedded samples from women with node-negative, estrogen-receptor–positive breast cancer was the basis for calculating a score for the risk of distant recurrence. The difference in risk between women with low and high recurrence scores was significant. The recurrence score also predicted overall survival.
An assay of 21 genes was the basis for calculating the risk of distant recurrence. The difference in risk between women with low and high recurrence scores was significant.
Over the past two decades, the molecular dissection of cancer has increased our understanding of the pathways that are altered in neoplastic cells.
1
,
2
Nevertheless, the diagnosis of cancer and decisions about its treatment still rely largely on classic histopathological and immunohistochemical techniques. A more quantitative approach to diagnosis and rational individualization of treatment are needed.
Large clinical trials, such as National Surgical Adjuvant Breast and Bowel Project (NSABP) trials B-14 and B-20, have demonstrated the benefit of tamoxifen and chemotherapy in women who have node-negative, estrogen-receptor–positive breast cancer.
3
–
5
However, since the likelihood of distant recurrence in patients treated . . . |
| doi_str_mv | 10.1056/NEJMoa041588 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67204044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>792904181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c613t-4c988c351e46da051140dbbc7d276c476d3a7ea8ceebbcf439b36befc045ae443</originalsourceid><addsrcrecordid>eNpt0EtLxDAQB_Agiq6Pm2cJop62mjSv9rguPllXkfXgqaTpVLq0zZq0ot_e6C4o4lwCwy8zwx-hfUpOKRHybHpxe2c14VQkyRoaUMFYxDmR62hASJxEXKVsC217PyehKE830RYVIqWMiQF6HuG7vu6qF2gBj7zXH7iz-MFBUZkOP4LpnYPWALYlnunGvlcltNHMge6gGOKpLSCawovuqjfA56HtOzzW4YPbRRulrj3srd4d9HR5MRtfR5P7q5vxaBIZSVkXcZMmiWGCApeFJoJSToo8N6qIlTRcyYJpBToxAKFbcpbmTOZQGsKFBs7ZDjpZzl04-9qD77Km8gbqWrdge59JFRNOvuHhHzi3vWvDbVkcs5QxJeOAhktknPXeQZktXNVo95FRkn3lnf3OO_CD1cw-b6D4wauAAzheAe2NrksXsqn8j5MsUSJWwR0tXdP4rIV58_--TzBWkm8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223933762</pqid></control><display><type>article</type><title>A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine</source><creator>Paik, Soonmyung ; Shak, Steven ; Tang, Gong ; Kim, Chungyeul ; Baker, Joffre ; Cronin, Maureen ; Baehner, Frederick L ; Walker, Michael G ; Watson, Drew ; Park, Taesung ; Hiller, William ; Fisher, Edwin R ; Wickerham, D. Lawrence ; Bryant, John ; Wolmark, Norman</creator><creatorcontrib>Paik, Soonmyung ; Shak, Steven ; Tang, Gong ; Kim, Chungyeul ; Baker, Joffre ; Cronin, Maureen ; Baehner, Frederick L ; Walker, Michael G ; Watson, Drew ; Park, Taesung ; Hiller, William ; Fisher, Edwin R ; Wickerham, D. Lawrence ; Bryant, John ; Wolmark, Norman</creatorcontrib><description>A polymerase-chain-reaction assay of 21 genes performed on paraffin-embedded samples from women with node-negative, estrogen-receptor–positive breast cancer was the basis for calculating a score for the risk of distant recurrence. The difference in risk between women with low and high recurrence scores was significant. The recurrence score also predicted overall survival.
An assay of 21 genes was the basis for calculating the risk of distant recurrence. The difference in risk between women with low and high recurrence scores was significant.
Over the past two decades, the molecular dissection of cancer has increased our understanding of the pathways that are altered in neoplastic cells.
1
,
2
Nevertheless, the diagnosis of cancer and decisions about its treatment still rely largely on classic histopathological and immunohistochemical techniques. A more quantitative approach to diagnosis and rational individualization of treatment are needed.
Large clinical trials, such as National Surgical Adjuvant Breast and Bowel Project (NSABP) trials B-14 and B-20, have demonstrated the benefit of tamoxifen and chemotherapy in women who have node-negative, estrogen-receptor–positive breast cancer.
3
–
5
However, since the likelihood of distant recurrence in patients treated . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa041588</identifier><identifier>PMID: 15591335</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Algorithms ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Deoxyribonucleic acid ; DNA ; DNA, Neoplasm - analysis ; DNA, Neoplasm - metabolism ; Estrogen Antagonists - therapeutic use ; Female ; Follow-Up Studies ; Gene Expression ; General aspects ; Genes, erbB-2 ; Gynecology. Andrology. Obstetrics ; Humans ; Lymphatic Metastasis ; Mammary gland diseases ; Medical sciences ; Methods ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis ; Prognosis ; Proportional Hazards Models ; Receptors, Estrogen ; Receptors, Progesterone ; Recurrence ; Reverse Transcriptase Polymerase Chain Reaction ; Review boards ; Risk ; Survival Analysis ; Tamoxifen - therapeutic use ; Tumors</subject><ispartof>The New England journal of medicine, 2004-12, Vol.351 (27), p.2817-2826</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><rights>2005 INIST-CNRS</rights><rights>Copyright 2004 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c613t-4c988c351e46da051140dbbc7d276c476d3a7ea8ceebbcf439b36befc045ae443</citedby><cites>FETCH-LOGICAL-c613t-4c988c351e46da051140dbbc7d276c476d3a7ea8ceebbcf439b36befc045ae443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa041588$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa041588$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26082,27903,27904,52360,54042</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16387527$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15591335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paik, Soonmyung</creatorcontrib><creatorcontrib>Shak, Steven</creatorcontrib><creatorcontrib>Tang, Gong</creatorcontrib><creatorcontrib>Kim, Chungyeul</creatorcontrib><creatorcontrib>Baker, Joffre</creatorcontrib><creatorcontrib>Cronin, Maureen</creatorcontrib><creatorcontrib>Baehner, Frederick L</creatorcontrib><creatorcontrib>Walker, Michael G</creatorcontrib><creatorcontrib>Watson, Drew</creatorcontrib><creatorcontrib>Park, Taesung</creatorcontrib><creatorcontrib>Hiller, William</creatorcontrib><creatorcontrib>Fisher, Edwin R</creatorcontrib><creatorcontrib>Wickerham, D. Lawrence</creatorcontrib><creatorcontrib>Bryant, John</creatorcontrib><creatorcontrib>Wolmark, Norman</creatorcontrib><title>A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>A polymerase-chain-reaction assay of 21 genes performed on paraffin-embedded samples from women with node-negative, estrogen-receptor–positive breast cancer was the basis for calculating a score for the risk of distant recurrence. The difference in risk between women with low and high recurrence scores was significant. The recurrence score also predicted overall survival.
An assay of 21 genes was the basis for calculating the risk of distant recurrence. The difference in risk between women with low and high recurrence scores was significant.
Over the past two decades, the molecular dissection of cancer has increased our understanding of the pathways that are altered in neoplastic cells.
1
,
2
Nevertheless, the diagnosis of cancer and decisions about its treatment still rely largely on classic histopathological and immunohistochemical techniques. A more quantitative approach to diagnosis and rational individualization of treatment are needed.
Large clinical trials, such as National Surgical Adjuvant Breast and Bowel Project (NSABP) trials B-14 and B-20, have demonstrated the benefit of tamoxifen and chemotherapy in women who have node-negative, estrogen-receptor–positive breast cancer.
3
–
5
However, since the likelihood of distant recurrence in patients treated . . .</description><subject>Algorithms</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA, Neoplasm - analysis</subject><subject>DNA, Neoplasm - metabolism</subject><subject>Estrogen Antagonists - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Expression</subject><subject>General aspects</subject><subject>Genes, erbB-2</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Metastasis</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Receptors, Estrogen</subject><subject>Receptors, Progesterone</subject><subject>Recurrence</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Review boards</subject><subject>Risk</subject><subject>Survival Analysis</subject><subject>Tamoxifen - therapeutic use</subject><subject>Tumors</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0EtLxDAQB_Agiq6Pm2cJop62mjSv9rguPllXkfXgqaTpVLq0zZq0ot_e6C4o4lwCwy8zwx-hfUpOKRHybHpxe2c14VQkyRoaUMFYxDmR62hASJxEXKVsC217PyehKE830RYVIqWMiQF6HuG7vu6qF2gBj7zXH7iz-MFBUZkOP4LpnYPWALYlnunGvlcltNHMge6gGOKpLSCawovuqjfA56HtOzzW4YPbRRulrj3srd4d9HR5MRtfR5P7q5vxaBIZSVkXcZMmiWGCApeFJoJSToo8N6qIlTRcyYJpBToxAKFbcpbmTOZQGsKFBs7ZDjpZzl04-9qD77Km8gbqWrdge59JFRNOvuHhHzi3vWvDbVkcs5QxJeOAhktknPXeQZktXNVo95FRkn3lnf3OO_CD1cw-b6D4wauAAzheAe2NrksXsqn8j5MsUSJWwR0tXdP4rIV58_--TzBWkm8</recordid><startdate>20041230</startdate><enddate>20041230</enddate><creator>Paik, Soonmyung</creator><creator>Shak, Steven</creator><creator>Tang, Gong</creator><creator>Kim, Chungyeul</creator><creator>Baker, Joffre</creator><creator>Cronin, Maureen</creator><creator>Baehner, Frederick L</creator><creator>Walker, Michael G</creator><creator>Watson, Drew</creator><creator>Park, Taesung</creator><creator>Hiller, William</creator><creator>Fisher, Edwin R</creator><creator>Wickerham, D. Lawrence</creator><creator>Bryant, John</creator><creator>Wolmark, Norman</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041230</creationdate><title>A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer</title><author>Paik, Soonmyung ; Shak, Steven ; Tang, Gong ; Kim, Chungyeul ; Baker, Joffre ; Cronin, Maureen ; Baehner, Frederick L ; Walker, Michael G ; Watson, Drew ; Park, Taesung ; Hiller, William ; Fisher, Edwin R ; Wickerham, D. Lawrence ; Bryant, John ; Wolmark, Norman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c613t-4c988c351e46da051140dbbc7d276c476d3a7ea8ceebbcf439b36befc045ae443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Algorithms</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA, Neoplasm - analysis</topic><topic>DNA, Neoplasm - metabolism</topic><topic>Estrogen Antagonists - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Expression</topic><topic>General aspects</topic><topic>Genes, erbB-2</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Metastasis</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Receptors, Estrogen</topic><topic>Receptors, Progesterone</topic><topic>Recurrence</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Review boards</topic><topic>Risk</topic><topic>Survival Analysis</topic><topic>Tamoxifen - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paik, Soonmyung</creatorcontrib><creatorcontrib>Shak, Steven</creatorcontrib><creatorcontrib>Tang, Gong</creatorcontrib><creatorcontrib>Kim, Chungyeul</creatorcontrib><creatorcontrib>Baker, Joffre</creatorcontrib><creatorcontrib>Cronin, Maureen</creatorcontrib><creatorcontrib>Baehner, Frederick L</creatorcontrib><creatorcontrib>Walker, Michael G</creatorcontrib><creatorcontrib>Watson, Drew</creatorcontrib><creatorcontrib>Park, Taesung</creatorcontrib><creatorcontrib>Hiller, William</creatorcontrib><creatorcontrib>Fisher, Edwin R</creatorcontrib><creatorcontrib>Wickerham, D. Lawrence</creatorcontrib><creatorcontrib>Bryant, John</creatorcontrib><creatorcontrib>Wolmark, Norman</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paik, Soonmyung</au><au>Shak, Steven</au><au>Tang, Gong</au><au>Kim, Chungyeul</au><au>Baker, Joffre</au><au>Cronin, Maureen</au><au>Baehner, Frederick L</au><au>Walker, Michael G</au><au>Watson, Drew</au><au>Park, Taesung</au><au>Hiller, William</au><au>Fisher, Edwin R</au><au>Wickerham, D. Lawrence</au><au>Bryant, John</au><au>Wolmark, Norman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2004-12-30</date><risdate>2004</risdate><volume>351</volume><issue>27</issue><spage>2817</spage><epage>2826</epage><pages>2817-2826</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>A polymerase-chain-reaction assay of 21 genes performed on paraffin-embedded samples from women with node-negative, estrogen-receptor–positive breast cancer was the basis for calculating a score for the risk of distant recurrence. The difference in risk between women with low and high recurrence scores was significant. The recurrence score also predicted overall survival.
An assay of 21 genes was the basis for calculating the risk of distant recurrence. The difference in risk between women with low and high recurrence scores was significant.
Over the past two decades, the molecular dissection of cancer has increased our understanding of the pathways that are altered in neoplastic cells.
1
,
2
Nevertheless, the diagnosis of cancer and decisions about its treatment still rely largely on classic histopathological and immunohistochemical techniques. A more quantitative approach to diagnosis and rational individualization of treatment are needed.
Large clinical trials, such as National Surgical Adjuvant Breast and Bowel Project (NSABP) trials B-14 and B-20, have demonstrated the benefit of tamoxifen and chemotherapy in women who have node-negative, estrogen-receptor–positive breast cancer.
3
–
5
However, since the likelihood of distant recurrence in patients treated . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>15591335</pmid><doi>10.1056/NEJMoa041588</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2004-12, Vol.351 (27), p.2817-2826 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67204044 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine |
| subjects | Algorithms Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Biomarkers, Tumor - analysis Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Deoxyribonucleic acid DNA DNA, Neoplasm - analysis DNA, Neoplasm - metabolism Estrogen Antagonists - therapeutic use Female Follow-Up Studies Gene Expression General aspects Genes, erbB-2 Gynecology. Andrology. Obstetrics Humans Lymphatic Metastasis Mammary gland diseases Medical sciences Methods Middle Aged Multivariate Analysis Neoplasm Metastasis Prognosis Proportional Hazards Models Receptors, Estrogen Receptors, Progesterone Recurrence Reverse Transcriptase Polymerase Chain Reaction Review boards Risk Survival Analysis Tamoxifen - therapeutic use Tumors |
| title | A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A23%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Multigene%20Assay%20to%20Predict%20Recurrence%20of%20Tamoxifen-Treated,%20Node-Negative%20Breast%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Paik,%20Soonmyung&rft.date=2004-12-30&rft.volume=351&rft.issue=27&rft.spage=2817&rft.epage=2826&rft.pages=2817-2826&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa041588&rft_dat=%3Cproquest_cross%3E792904181%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223933762&rft_id=info:pmid/15591335&rfr_iscdi=true |